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Meshed, split-thickness skin grafts, especially when required to be widely spread, do
not obtain immediate biologic closure. In patients with burns that cover a large per-
centage of the body surface area, this leaves the patient at risk for metabolic problems
and life-threatening infection. Objective: The purpose of this study was to determine
whether amnion-derived cellular cytokine solution could improve epithelialization ki-
neticsandaccelerateclosureofmeshedskingraftinterstices.Methods:Humanmeshed,
split-thickness skin grafts were explanted to athymic “nude” rats and treated with 3 dif-
ferent regimens of amnion-derived cellular cytokine solution (groups I, II, and III) or
normal saline (group IV) as a control. Serial wound tracings of unepithelialized intersti-
tialwoundareaswerecomparedovertime.Twodifferentpreparationsofamnion-derived
cellular cytokine solution were also compared with one another, one containing animal
components and the other free of animal components. Results: Only 67.03% of inter-
stices in control animals closed by day 9. This compared with 92.2% closure for group
I, 83.72% for group II, and 90.64% for group III. Interstices in all 3 groups treated with
amnion-derived cellular cytokine solution (with or without animal-derived components)
closed faster statistically than in the control animals (P < .05). There were no statisti-
cal differences among the 3 amnion-derived cellular cytokine solution–treated groups.
Conclusions:Thesedatasuggestthatepithelializationkineticsandinterstitialclosureof
meshed skin grafts can be accelerated with the use of amnion-derived cellular cytokine
solution, a physiologic cocktail of cytokines, and provide support for a future clinical
trial.
Amnion-derived multipotent progenitor (AMP) cells serve as the basis for a platform
technology being developed for the treatment of burn wounds.1,2 These cells are isolated
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fromthenoncontroversial,full-termplacentaandareunlikemoststemcellsinthattheyhave
been demonstrated to be nontumorigenic and nonimmunogenic.3 Amnion-derived cellular
cytokine solution (ACCS), a secreted product of AMP cells, is a cocktail of cytokines
existing at physiologic levels.4 It is being developed to treat 4 types of burn wounds:
the partial-thickness burn, which, if protected, can heal by epithelialization; the excised
full-thickness burn, which will eventually have to be closed; the interstitial wounds seen
in meshed skin grafts; and the skin graft donor site. Meshed, split-thickness skin grafts,
especially when required to be widely spread, do not obtain immediate biologic wound
closure.5 In patients with burns that cover a large percentage of total body surface area, the





accelerates interstitial wound closure in human meshed skin grafts.
MATERIALS AND METHODS
An animal model of human meshed, split-thickness skin grafts explanted onto athymic
“nude” rats was used to evaluate ACCS as a cocktail of physiologic cytokines.5–7 This
model allows for the accurate measurement of closure of graft interstices serially over time.
The ACCS was prepared for the experiment as follows: The AMP cells were grown to
confluency in 1 of 2 serum-free media. The first contained animal-derived components
and the second contained no animal-derived components. Once the cells had grown to
confluency, using proprietary techniques, the supernatant was harvested as ACCS.
Same-day, birth-dated, congenitally outbred, athymic “nude” rats (Harlan Sprague
Dawley Inc, Indianapolis, Ind) weighing 250 to 300 g were used. Because of their im-
munocompromised state, the animals were housed in a pathogen-free barrier facility and
individually caged in microisolators that were kept in a laminar-flow room.5–7 All animal
supplies, such as food, water, and bedding, were sterilized by autoclave before use. The rats
received food and water ad libitum. Sterile gloves, gowns, caps, and shoe covers were worn
at all times by personnel who were handling the animals. All surgery was performed with
the use of strict aseptic techniques and under laminar-flow hoods. All experiments followed
a protocol approved by the Bay Pines VAHCS Animal Care Use Committee and complied
with the National Research Council’s criteria for humane care of animals.
Twenty male, athymic “nude” rats were divided into 4 equal groups of 5 animals each
(120 interstitial wounds per animal or 600 wounds per group) to have their skin grafts
treated with ACCS (free of animal-derived components) at 0.01 mL/cm2 daily (group I)
or on alternate days (group II); original ACCS (with animal-derived components) at 0.01
mL/cm2 daily (group III), or with 0.9% NaCl daily (group IV) as a control. Fresh split-
thickness human skin was meshed 1:1.5 with the use of aseptic techniques. Contracts with
a commercially available, certified tissue bank specified that the skin used be harvested
from a single site on a single cadaveric donor with an electric dermatome. The skin was
0.014- to 0.020-in thick. Skin sample cultures and donor serology confirmed that the tissue
was negative for pathogenic organisms, hepatitis B and C viruses, and HIV. Cell viability
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Figure 1. A 30-cm2 defect on the dorsum of a “nude” rat.
immediately before explantation was confirmed to be more than 90% according to the
Trypan Blue exclusion test.
With the use of strict aseptic techniques and working within a unidirectional airflow
biologic hood, the rats were anesthetized with intraperitoneal pentobarbital (Nembutal) at
a dose of 35 mg/kg body weight. After the dorsal skin was treated with povidone-iodine
solution, a standardized full-thickness area (30-cm2) of skin and panniculus carnosa were
excised (Fig 1). The meshed skin graft was pinned to a corkboard that had a cutout area
the same size as the wound that was inflicted to each animal.6,7 The graft was then spread
to the greatest degree possible in an effort to maximize the extent of graft interstices. This
maximally spread meshed graft was then grafted to the wound on the animal and fixed
with staples to the surrounding wound edges (Fig 2). The grafts were treated with the test
solutions by pumping the solutions from a pump actuator at a rate of 0.01 mL/cm2 of graft.
The grafts were dressed with N-Terface nonadherent gauze (Winfield Laboratories, Inc,
Richardson, Tex) and covered with an 8-ply gauze dressing.
Standardized photography of the grafts was performed before the initial dressing and
daily thereafter (Fig 3). The dressing was changed at the time that the daily photograph was
taken. A digital, single-lens reflex camera with a macro lens was mounted onto a camera
stand. A centimeter ruler was included in each photograph. The photographs were analyzed
and an arbitrarily sized designated analysis area was chosen in the central area of each
graft. With the use of planimetry software, the grafts were analyzed as had been done in
previous studies.5–7 The interstitial areas that remain open within the designated analysis
area of each graft were measured. Neoepithelial areas were calculated by subtracting daily
measurementsofinterstitialareasfromtheoriginalmeasurementsofthoseinterstitialareas.
A percentage of neoepithelialization was then determined for designated analysis area by
the following equation:
PercentageNeoepithelialization = (NeoepithelialArea / DesignatedAnalysisArea) × 100
Data from each day were compared among the 4 groups by 1-way analysis of variance
and between pairs of groups by the Fisher least significance difference test with an α value
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Figure 2. A maximally spread, meshed, split-thickness skin graft on a “nude” rat.
Figure 3. The photograph of a “nude” rat in group II on day 6 demonstrating complete epithelial-
ization of some interstices and partial epithelialization of other interstices.
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of .05. Histologic sections were obtained through the meshed graft interstices on day 9 to
demonstrate that the interstices have closed by the process of epithelialization rather than
contraction.
RESULTS
Seventeen of the animals achieved variable closure of interstices by epithelialization. The
dressings were slightly adherent in 3 animals so as to possibly disrupt the new epithelium.
Therefore, these 3 animals were eliminated from statistical evaluation (1 animal each from
groupsI,III,andIV).Becausetheepithelializationratewaslevelingoffbyday9,theanimals
were humanely euthanized on day 10. Only 67.03% of the interstices in control animals
closed by day 9 (Fig 4). This compared with 92.2% closure for group I, 83.72% for group





the difference was not statistically significant. The model showed comparability between
ACCS prepared with media containing animal-derived components (group III) and ACCS
prepared without animal-derived components (groups I and II). Histology of sections from
groups I to III were identical, demonstrating that normal epithelialization occurred in all
healed grafts and that interstices closed by epithelialization and not by contracture.
DISCUSSION
Early excision and wound closure have significantly decreased mortality and morbidity of
patients with burns. Available donor sites for autologous skin grafts decrease as the total
size of the burn wound in need of excision increases. Meshing of the skin grafts allows
an increase in the area a given graft can cover. However, the open area of the meshed
graft interstices is similar to all open wounds; it increases the metabolic demand on the
patients and they remain prone to life-threatening invasive infection.5,7 Because several
single growth factors have been shown to improve epithelialization kinetics and accelerate
interstitial wound closure in mesh grafts,5 it was hypothesized that a cocktail of growth
factors would be similarly effective.




in their cocktail. These 6 cytokines were PDGF, VEGF, angiogenin, TGF-β2, TIMP-1, and
TIMP-2. The levels of the 6 naturally occurring cytokines in ACCS were compared with
levels of those cytokines from normally healing wounds reported in the literature.4 ACCS
was determined to contain 6 cytokines at physiologic levels. It was for this reason that
ACCS was postulated to be effective in these wounds. The single growth factors reported
in this model by Smith et al5 were at higher levels than the physiologic levels in ACCS.
Also, ACCS has TIMP-1 and TIMP-2 in it, which can inhibit matrix metalloproteinases
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Figure 4. Epithelialization rates of 600 wounds per group: group I, amnion-derived cellu-
lar cytokine solution (ACCS) without animal-derived components, daily treatment; group II,
ACCS without animal-derived components, every other day treatment; group III, ACCS con-
taining animal-derived components, daily treatment; and group IV , saline daily. ∗P <. 05.
produced in the open granulating wounds.10 The first ACCS harvested was from AMP
cells grown in a medium containing animal-derived components. Following success with
several proof-of-concept experimental wound healing models, AMP cells were grown in a
medium free of animal-derived components, as would be required for future clinical trials.
Therefore, ACCSs produced in both media were used in this study.
There was no observed toxicity among the animals. All survived the experiment. The
dressingsof3animalsadheredtotheirwoundsandtheseanimalswere,therefore,eliminated
from statistical evaluation because the rate of epithelialization might have been affected.
Thedosewas0.01mL/cm2 foreachapplicationofACCSornormalsaline.GroupsI,III,and
118UBERTI ET AL
IV had the application daily and group II had the application every other day. Although the
daily application of ACCS developed in either medium allowed faster epithelialization than
the every other day application, these differences were not statistically significant (Fig 4).
ItisclearthatACCSimprovedepithelializationkineticsandacceleratedwoundclosure
inthismodel.BothACCSpreparationswereeffective.TheimportanceoftheACCSwithout
animal components is that the Food and Drug Administration desires that biologic products
do not contain animal components when used in clinical trials. Because human meshed
skin grafts were used with ACCS from a human source, there is reason to believe that the
resultsmaybeextrapolatedtothehumansituation.Smallanimalexperimentswillnotallow
definitivedose-responsedata,whichwillhavetobedeterminedduringhumanclinicaltrials.
Therefore, the next step in confirming the efficacy of this treatment would be to perform a
prospective,randomized,blinded,placebo-controlledclinicaltrialthatwouldtesttheability
of ACCS to accelerate the interstitial closure of meshed skin grafts in patients with burns.
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